Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2012-01-13 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is a media release announcing a restructuring plan in the US business due to the loss of patent exclusivity and clinical trial results impacting sales. It includes details about charges, restructuring impacts, and forward-looking statements. There are no actual financial statements or detailed financial data presented, only an announcement of corporate actions and financial impacts. The document is not an annual or interim report, audit report, earnings release, or any detailed financial report. It is a regulatory filing providing material corporate news and updates to the SEC and investors. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (12,545 characters) and content confirm it is not a brief announcement but a full regulatory filing of a corporate update, fitting the RNS category.
2012-01-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of a media release about a voluntary recall of certain over-the-counter products in the US, details about the recall, quality standards, and a one-time charge related to the recall. There are no financial statements or detailed financial analysis present. The document is a regulatory announcement informing the public and investors about the recall and related operational updates. It does not contain quarterly or annual financial results, audit opinions, or management discussions typical of financial reports. Given the nature of the filing (Form 6-K) and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-01-10 English
Regulatory Filings 2011
Regulatory Filings
2011-12-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the termination of the ALTITUDE clinical study due to safety concerns. It includes details about the study, the decision to terminate, and the implications for the product Rasilez/Tekturna. There are no financial statements or detailed financial analysis present, only an announcement of a clinical trial termination and related business impact. The document is about a regulatory update and corporate announcement rather than a financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, or Management Discussion. It is also not a proxy, voting result, or governance document. The document is a regulatory announcement filed on Form 6-K, which is typically used for current reports by foreign private issuers. Therefore, the best fitting category is Regulatory Filings (RNS). The document length (11,850 characters) is sufficient to be a full announcement rather than a brief report publication announcement.
2011-12-20 English
SC 13D/A
Major Shareholding Notification
2011-12-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing positive clinical trial results for the drug Gilenya. It includes detailed clinical data, safety information, and forward-looking statements. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. Instead, it is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. The document is lengthy (15,000 characters) and contains substantive information, but it is not a financial report or earnings announcement. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-12-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.